MSON.B

10.5

+2.94%↑

MSON.B

10.5

+2.94%↑

MSON.B

10.5

+2.94%↑

MSON.B

10.5

+2.94%↑

MSON.B

10.5

+2.94%↑

Начало・Списък с акции・Vivesto AB

Vivesto AB

Отворен

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Ключови измерители
By Trading Economics
Приходи	2.3M -7.2M
EPS	-0.013
Служители	4
EBITDA	-7.1M

Дивиденти
By Dow Jones
Следващи печалби	27.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-23M 55M
Предишно отваряне	0
Предишно затваряне	0

Vivesto AB Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.02.2026 г., 23:11 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting All-Time High -- Market Talk

3.02.2026 г., 23:42 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Technical Correction -- Market Talk

3.02.2026 г., 23:41 ч. UTC

Придобивния, сливания и поглъщания

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3.02.2026 г., 23:38 ч. UTC

Печалби

AMD Sales Climb on Help From Data-Center Business -- Update

3.02.2026 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3.02.2026 г., 23:27 ч. UTC

Придобивния, сливания и поглъщания

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3.02.2026 г., 23:25 ч. UTC

Придобивния, сливания и поглъщания

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3.02.2026 г., 23:23 ч. UTC

Придобивния, сливания и поглъщания

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3.02.2026 г., 23:22 ч. UTC

Придобивния, сливания и поглъщания

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3.02.2026 г., 23:19 ч. UTC

Пазарно говорене

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3.02.2026 г., 23:19 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.02.2026 г., 22:56 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3.02.2026 г., 22:40 ч. UTC

Печалби

Amdocs Extends Collaboration With T-Mobile

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q Adj EPS $1.81

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q Rev $1.16B

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q EPS $1.45 >

3.02.2026 г., 22:38 ч. UTC

Печалби

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3.02.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3.02.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3.02.2026 г., 22:14 ч. UTC

Печалби

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3.02.2026 г., 22:13 ч. UTC

Печалби

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3.02.2026 г., 22:12 ч. UTC

Печалби

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3.02.2026 г., 22:10 ч. UTC

Печалби

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3.02.2026 г., 22:10 ч. UTC

Печалби

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3.02.2026 г., 22:10 ч. UTC

Пазарно говорене

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3.02.2026 г., 22:10 ч. UTC

Печалби

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3.02.2026 г., 22:09 ч. UTC

Печалби

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3.02.2026 г., 22:09 ч. UTC

Печалби

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Сравнение с други в отрасъла

Ценова промяна

Vivesto AB Прогноза

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.

Други акции от сектора

MSON.B

Midsona AB

10.5

↑ +2.94%

Vivesto AB

Преглед

Промяна на цената на акция

Ключови измерители

Дивиденти

Пазарни показатели

Vivesto AB Графика

Свързани новини

Сравнение с други в отрасъла

Vivesto AB Прогноза

Финанси

Относно Vivesto AB

Други акции от сектора